Hereditary myopathy with lactic acidosis, or myopathy with exercise intolerance, Swedish type (OMIM #255125) is caused by mutations in the iron-sulfur cluster scaffold (ISCU) gene. The g.7044G N C ISCU mutation induces a splicing error in the pre-mRNA that strengthens a weak intronic splice site leading to inclusion of a new exon and subsequent loss of mRNA and protein. While ISCU is widely expressed, homozygosity for this particular intronic mutation gives rise to a pure myopathy. In order to investigate tissue specificity and disease mechanism, we studied muscle, myoblasts, fibroblasts and blood cells from the first non-Swedish case of this disease. Consistent with the recognised role of ISCU, we found abnormal activities of respiratory chain complexes containing iron-sulfur clusters in patient muscle. We confirmed that, in the presence of the g.7044G N C mutation, splicing produces both abnormally and normally spliced mRNA in all tissues. The ratio of these products varies dramatically between tissues, being most abnormal in mature skeletal muscle that also has the lowest relative starting levels of ISCU mRNA compared with other tissues. Myoblasts and fibroblasts have more of the normally spliced variant as well as higher starting levels of ISCU mRNA. Up-regulation of mtDNA copy number was found in skeletal muscle and myoblasts, but not fibroblasts, and is thought to represent a compensatory response. Tissue specificity in this disorder appears therefore to be dependent on the mRNA starting level, the amount of remaining normally spliced RNA, and the degree to which compensatory mechanisms can respond.
Introduction
Syndromes of exercise intolerance with or without rhabdomyolysis can be caused by a variety of metabolic disorders including those affecting glycogen [1] and lipid metabolism [2] and mitochondrial disorders [3, 4] . Hereditary myopathy with lactic acidosis was described by Larsson and Linderholm in five families from Northern Sweden in the early 1960s. The disease, which is characterised by childhood onset exercise intolerance with muscle tenderness and cramping, dyspnoea and palpitations, is transmitted as an autosomal recessive trait (OMIM #255125) [5] . It is usually non-progressive, although two cases of fatal myoglobinuria [6] and some with fixed muscle weakness [6, 7] have been reported.
Recently, two reports concurrently identified an intronic point mutation (g.7044G N C, GenBank accession number EU334585) in the iron-sulfur cluster scaffold (ISCU) gene [8, 9] as the cause of this disorder. A more severe phenotype has also been described in compound heterozygous patients having the g.7044G N C together with an exon 3 missense mutation [7] .
The ISCU protein is involved in the assembly of iron-sulfur (FeS) clusters, essential components of several cellular proteins including mitochondrial respiratory chain complexes I, II and III and aconitase of the citric acid cycle [10] . Mitochondrial (ISCU 2) and cytosolic (ISCU 1) isoforms of ISCU arise from alternative splicing of the first exon yielding two transcript variants (GenBank NM_014301.3 for ISCU 1 and NM_213595.2 for ISCU 2) [11] . The recently described g.7044G N C mutation in the ISCU gene strengthens a weak splice acceptor site leading to the inclusion of an abnormal exon, hereafter referred to as 5A between the two last exons 5 and 6, thus affecting both transcript variants. Inclusion of exon 5A introduces a premature stop codon, leading to protein truncation by 13 amino acids and was reported to destabilise the transcript leading to ISCU mRNA depletion [8, 9] . While loss of functional ISCU protein is presumably the cause of the biochemical defects described, it is not clear why this disease is clinically restricted to skeletal muscle.
We report the first non-Swedish case of this disease in a patient of Norwegian descent who is homozygous for the g.7044 G N C mutation.
Our studies confirm that the aberrant splicing of the ISCU gene occurs not only in the patient but also at very low levels in controls. Our findings suggest that it is the ratio of normally versus abnormally spliced intermediate, as well as different steady-state levels of ISCU transcript and the degree to which tissues can compensate the loss of ISCU that dictates clinical expression.
Materials and methods

Patient
The patient is currently 25 years old and was born in southern Norway to non-consanguineous parents. Similar to the Swedish patients described previously [5] , she developed exercise intolerance in childhood, experiencing shortness of breath, palpitations and fatigue at low to moderate levels of physical activity. Following exercise her muscles become tender and swollen. The course has been variable with periods when she has good physical stamina and is able to lead a near normal life, to periods when she can barely get out of bed due to muscle pain and fatigue. Two episodes of documented rhabdomyolysis required intensive care treatment, and both were followed by proximal muscle weakness that subsided over a few weeks. On one of these occasions, CK rose to ∼ 300 000. When examined in a quiet phase of disease, she had a normal neurological examination. Resting lactic acidosis (∼ 4 mM; normal range of 0.4-1.7 mM) was noted on one occasion, but CK levels were normal.
The patient has had two diagnostic muscle biopsies (ages 15 and 19). In the first biopsy, electron microscopy showed some subsarcolemmal mitochondrial accumulation, lipid droplet accumulation and electron dense inclusions in abnormally shaped mitochondria. No ragged-red or cytochrome c oxidase-deficient fibres were seen in either biopsy. Histochemical analysis of myophosphorylase and other glycogen metabolism enzymes studied were normal, as was acylcarnitine profile in fibroblasts and CPTII activity in whole muscle. The patient was referred to our Diagnostic Centre for Mitochondrial disease for further evaluation, and open skeletal muscle biopsy was performed under local anaesthesia from vastus lateralis. Tissue sampling was done as part of the clinical work-up and the subsequent research project was approved by the Regional Committee for Medical and Health Research Ethics, University of Bergen, Norway with the written consent of the patient.
Muscle sampling and myoblast culture
Skeletal muscle samples for biochemical analysis, RNA and protein studies were frozen immediately in isopentane pre-chilled in liquid nitrogen and stored at −80C. Muscle tissue for myoblast culture collected in cold DMEM was cut into 1 mm × 1 mm pieces, left to adhere on culture plates covered with DMEM growth medium supplemented with 20% (v/v of DMEM) fetal bovine serum, 1.9 mM L-glutamine, 1% (v/v of DMEM) chick embryo extract, 79.7 U/ml penicillin-streptomycin, 0.8 mM pyruvate and 0.16 mM uridine, mixed 1:1 with sterile filtered conditioned medium (24 h on muscle derived fibroblasts) and incubated at 37°C, 5% CO 2 . Cells growing out from the explants were harvested around day 14 and subcultured in pure supplemented growth medium. In order to minimize fibroblast contamination, cell suspensions were pre-plated on culture dishes for 20 min at each passage and 40 min for the final passage before protein and RNA preparation. Myoblast purity was estimated in parallel suspensions by fluorescence microscopy and Desmin staining as described [12] , with shorter washes (10 min), and was N90% after 48 h incubation. Cells for biochemical measurements were maintained in skeletal muscle cell growth medium kit (Promocell, Heidelberg, Germany) plus 10% fetal bovine serum, supplemented with 2.7 mM L-glutamine and 5.38 μg/ml gentamycin. Clonetics ® human skeletal muscle myoblasts in designated growth medium (Lonza, Basel, Switzerland) were used as controls for the myoblast protein studies and skeletal muscle from non-myopathic patients, sampled and cultured as described above, were used as controls for mitochondrial DNA (mtDNA) RNA, one-dimensional Blue-Native (BN) PAGE and ISCU protein western blotting studies on skeletal muscle and RNA studies on myoblasts.
Fibroblast culture
A punch skin biopsy was taken from the patient's upper arm, trimmed, cut into pieces and incubated in Amniochrome II complete medium (Lonza, Verviers, Belgium) at 37°C, 5% CO 2 . Fibroblasts growing out from the explant were maintained in DMEM growth medium with 10% fetal calf serum, 2 mM L-glutamine, 1% nonessential amino acid solution (Sigma, USA), 100 U/ml penicillinstreptomycin, 1 mM pyruvate and 0.2 mM uridine. Normal human dermal fibroblasts (NHDF-p, PromoCell, Heidelberg, Germany), maintained in designated growth medium, were used as controls for the protein and RNA studies.
Respiratory chain function and assembly
Respiratory chain complex activity measurements were performed on mitochondrial fractions from frozen skeletal muscle, cultured skin fibroblasts and from primary myoblasts as described [13] . Homogenates of frozen skeletal muscle (20 mg) or cultured fibroblasts (2 × 75 cm 2 flasks) were prepared for BN PAGE as described [14] and protein concentrations determined by Bradford assay. Samples were analysed on 5-15% polyacrylamide gels: for Western blotting, 40 μg of muscle protein or 60 μg of fibroblast protein, and for in-gel activity measurement, 75 μg of fibroblast protein was used. Complex I in-gel activity assay was performed as described [14] , with shortened NADH/NTB incubation time (3 h). Following electrophoresis, proteins were denatured by incubating gels 30 min with 1% SDS and 1% ß-mercaptoethanol in water, and transferred to nitrocellulose membranes. These were blocked in 5% (w/v) milk/0,1% Tween-TBS (MTTBS) and incubated with primary antibody (mouse anti-complex I 30 kDa, anti-complex II 70 kDa at 1:1000 and anti-complex IV COX 1 at 1:10,000 dilution (MitoSciences, Eugene, Oregon, USA) in 5% MTTBS). Rabbit anti-mouse HRP antibody diluted 1:1000 was used as secondary antibody and signal was visualised using the ECL Plus kit (GE Healthcare, UK).
DNA analysis
Total DNA was isolated from blood, cultured cells and skeletal muscle using QIAmp DNA mini kit (QIAgen, Hilden, Germany). The ISCU mutation was identified by sequencing a 637 bp fragment of the ISCU gene (GenBank accession number NG_011857.1) amplified by the following primers, forward 5′-GGTTTGCAACAGTCCTTTTAGATCA and reverse primer 5′-CCATCGATGCATTAA GGCTAA.
Sequencing of the entire mtDNA was performed as previously described [4] . Long-range PCR (LPCR) to investigate mtDNA rearrangements, and real-time PCR (qPCR) analysis of mtDNA copy number were performed as described [15] . For the mtDNA qPCR study on cells, pellets remaining after removal of mitochondrial enriched supernatant for the biochemical assay were used for DNA extraction.
Homozygosity mapping was performed using the Affymetrix 250K-chip (Affymetrix, Santa Clara, CA, USA).
ISCU protein studies
Protein extracts were prepared from skeletal muscle by total protein extraction kit (Chemicon (Millipore), Billerica, MA, USA). Cultured cells (confluent 25 cm 2 flasks) were collected by trypsinization, pelleted and lysed in 0.15 M NaCl, 5 mM EDTA pH 8, 1% Triton X-100, 10 mM Tris-Cl pH 7.4, 5 mM DTT, 0.1 mM PMSF and 5 mM ε-aminocaproic acid. Lysates were centrifuged for 10 min at 17,500 g and protein concentration of the supernatant was determined by BCA™ protein assay kit (Thermo Scientific, Waltham, MA, USA). 40 μg of each sample was denatured in buffer containing 8 M urea, 2% ß-mercaptoethanol and 5% SDS for 2 h at 37°C (final urea concentration N2 M), separated on 15% denaturing polyacrylamide gels containing 6 M urea and electroblotted to nitrocellulose membranes. After blocking in 3% (w/v) milk/ phosphate buffered saline (PBS), these were incubated with rabbit anti-(full-length) ISCU 1/2 and rabbit anti-actin, both at 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) simultaneously, followed by goat anti-rabbit secondary antibody incubation (Southern Biotech, Birmingham, AL, USA) and ECL developing as above.
RNA studies
Total RNA was extracted from frozen muscle biopsies (∼ 20 mg) and cultured cells (confluent 25 cm 2 flask) using the Trizol reagent (Life Technologies, Carlsbad, CA, USA) as recommended by the manufacturer. RNA was extracted from full blood collected in PAXgene™ (PreAnalytiX, Switzerland) tube using QIAshredder and RNeasy Mini Kit (Qiagen, Hilden, Germany). For the splice variants study, RNA was reverse transcribed with either Superscript II reverse transcriptase or Multiscribe/TaqMan reverse transcription reagents (Life Technologies, Carlsbad, CA, USA). In the initial muscle study Superscript II cDNA was amplified with the primers 5-F (5′-GATATCGCCAAGGAGCTCTG) and 6-R (5′-TCATTTCTTCTCTGCCTCTCC) or 5a-R (5′-GACCAAACTGGAAAGCCAAG) ( Fig. 1 ) under standard conditions. Subsequent studies were done with Multiscribe cDNA. After separation on 3% GTG agarose gels, PCR products were purified by QIAquick gel extraction kit (Qiagen, Hilden, Germany) and sequenced using the same primers shown above on an ABI 3130XL Genetic Analyzer (Applied Biosystems). For the ISCU qPCR studies, 100 ng of RNA was reverse transcribed using the TaqMan reverse transcription reagents (Life Technologies, Carlsbad, CA, USA). PCR reactions were performed with the Applied Biosystems 7500 Fast instrument using the TaqMan Gene Expression Assays (Life Technologies, Carlsbad, CA, USA) for ISCU (Hs00396806_m1), detecting the exon boundary 4-5 and GAPDH as endogenous control. Patient skeletal muscle or myoblasts were compared to the average of 3 independent controls. Patient fibroblasts from skin or muscle origin were compared to one control for each.
Results
Predominant muscle defect of iron-sulfur cluster containing respiratory chain complexes
Activities of mitochondrial respiratory chain complexes I, II and III in the homogenate of frozen skeletal muscle were substantially decreased while the activity of complex IV was normal (Table 1) . One-dimensional Blue-Native polyacrylamide gel electrophoresis (BN PAGE) followed by Western blotting showed a decreased amount of complex I in muscle homogenate compared with controls, but normal levels of complex II (Fig. 2) . No abnormal assembly intermediates of either complex were seen. Biochemical measurements showed low complex II activity in fibroblasts, but apart from this, cultured myoblasts and skin fibroblasts had normal respiratory chain function (Table 1) . Similarly, in-gel-activity of complex I as well as Western blotting of complexes I and II following BN PAGE was normal in fibroblast mitochondrial fractions compared with controls (Fig. 2) . splicing has occurred, and a 630 bp fragment (IV) from the native, unspliced transcript, but will not work on correctly spliced (5 to 6) transcripts due to removal of the 5a-R site. B) RT-PCR on RNA isolated from skeletal muscle from the patient (1,6) and two controls (2,7 and 3,8) . Primers 5-F/6-R (5-8) amplify the 134 bp product (I) consisting of exons 5 + 6, as well as the aberrant 234 bp product (II), consisting of exons 6 + 5A + 6. In the patient (6), the aberrant transcript (II) dominates over the normal transcript (I), which is predominant in both controls (7) (8) . Intronic reverse primer 5a-R was used (1-4) to amplify the aberrant 5 + 5A species at 261 bp (III) which, in the patient (1), dominates over the unspliced precursor at 649 bp (IV). The opposite is the case in the controls (2) (3) . No PCR products were observed in negative controls (4) (5) . (L) -DNA ladder, bp. (*) -species identified by sequencing. C) Preservation (%) of normal ISCU splicing variant in different tissues from our patient and controls. PCR products amplified using primers 5F/6R. The proportions (% ± SD) of product I to the total amount of spliced transcripts (I + II) in repeated (N) RT-PCRs, estimated from ethidium bromide fluorescence. 1 -patient skeletal muscle (N = 8); 2 -patient myoblast (N = 6); 3 -patient fibroblast (N = 5); 4 -patient blood (N = 5); 5 and 6 -skeletal muscle controls (N = 6 + 7) (mean value calculated); 7 -myoblast control (N = 5); 8 -fibroblast control.
Identification of the first non-Swedish case of ISCU myopathy
Based on the patient's clinical presentation and biochemical defects involving mitochondrial respiratory chain complexes containing iron-sulfur clusters, direct sequencing of the ISCU gene was undertaken. This showed that our patient was homozygous for the recently published g.7044G N C ISCU transversion mutation [8, 9] . Her parents were heterozygous (chromatograms in Supplementary material). Haplotyping showed that the patient is homozygous for a 1.5 Mb region on chromosome 12 containing the ISCU gene (SNP_A-1661732-SNP_A-1743899) (Supplementary material), comprising much of the homozygous region found in a previous publication [8] .
ISCU protein is present in lowered amounts in skeletal muscle and cultured cells
The full-length ISCU 1/2 antibody used for Western blotting is predicted to identify both the 15 kDa cytoplasmic (ISCU 1) and 14 kDa mitochondrial isoforms (ISCU 2) [16] . In controls, we identified only a single species migrating at approximately 15 kDa. This was clearly decreased in the patient's muscle homogenate. ISCU levels in patient myoblasts and skin fibroblasts were also decreased (Fig. 2) . Incubation with an ISCU 1-specific antibody identified a band of identical molecular weight (not shown), suggesting either that the band detected by the ISCU 1/2 antibody represents the cytoplasmic isoform, that the antibody specificities are sub-optimal or that the two isoforms have not been sufficiently separated by electrophoresis. A dominant ISCU 1/cytoplasmic ISCU band is contrary to some previous findings [16] , but corresponds well with the recent study of Kollberg et al. who found that the major of two ISCU bands present in whole cell extracts disappeared in the membrane organelle protein fraction [7] . Both ISCU isoforms should, however, be affected by the mutation. An additional, faint product running just in front of the main ISCU band, possibly representing the 13 amino acid truncated ISCU, was visible in the patient's muscle and myoblast samples but not in fibroblasts (Fig. 2) .
Tissues are differently affected by ISCU RNA loss and splicing abnormalities
The steady-state level of ISCU mRNA estimated by qPCR was significantly decreased in patient myoblasts (20% of controls), moderately decreased in patient muscle (54% of controls) and unchanged in patient fibroblasts. In control tissues, the expression of ISCU relative to a control gene, was 3.5-4-fold higher in cultured cells than in skeletal muscle. In addition to differences in the steady-state levels of ISCU transcript, we also observed clear qualitative differences in the splicing products from different tissues. Amplification of skeletal muscle cDNA using primers 5-F/6-R (Fig. 1A) showed that the predominant transcript in the patient contained exons 5 + 5A + 6. This was confirmed by sequencing of gel products. In controls, the major band was the normally spliced species with exons 5 + 6 (Fig. 1) . A faint 5 + 6 band was found in the patient and a band corresponding by size to the abnormal transcript also seen in the controls, implying, as has previously been suggested [8] , that the mutation does not create a new splice site, but rather strengthens a pre-existing weak one (Fig. 1) . Bands 5 + 6 and 5 + 5A + 6 were also detectable in cDNA from patient myoblasts, fibroblasts and blood (Fig. 1C) . The proportion of correctly spliced transcript (134 bp/134 + 234) in each sample was calculated from ethidium bromide fluorescence intensities using Gene Snap and Gene Tools software (Syngene, Cambridge, UK). Mean values from replicate PCRs are shown in Fig. 1C . Results from cDNA generated either by oligo dT or random hexamer priming were similar and were therefore pooled. In patient muscle, approximately 10% of total transcript appears normally spliced while in controls this species comprises 90% of the total. In patient's myoblasts, fibroblasts and blood, both transcripts appear to present in approximately equal amounts. Similar results were obtained over a wide range of cDNA concentrations (0.015 ng-0.6 ng/μl PCR reaction).
Using exon primer 5-F and intron primer 5a-R to span the 5-5A splice junction and subsequent sequencing of PCR products, we found both the aberrantly spliced transcript and the unspliced precursor in patient and control muscle, thereby confirming that 5-5A splicing occurs even in normal skeletal muscle. The abnormally spliced 5-5A transcript predominates over the native transcript in the patient, while the reverse is found in control muscle (Fig. 1B) . While this PCR assay seems to yield substantial amounts of the aberrant transcript in control muscle, this assay analyses mRNA precursors and not mature mRNA, thus it is the ratio between spliced and unspliced precursor that is important.
Mitochondrial DNA is structurally intact, but increased in amount
Whole mitochondrial DNA sequencing revealed only known polymorphisms [17, 18] , while LPCR revealed no evidence of mtDNA rearrangements. Quantitative real-time PCR revealed, however, an approximate 6-fold increase in the amount of mtDNA in the patient's skeletal muscle compared with controls, a 17-fold increase in mtDNA copy number in patient myoblasts, but normal mtDNA levels in both fibroblasts and blood.
Discussion
We report the first case of ISCU-deficient hereditary myopathy with lactic acidosis outside Sweden. Our patient presented with severe exercise intolerance and rhabdomyolysis, but common causes including defects of glycogen and fatty acid metabolism were quickly excluded. Biochemical defects in mitochondrial respiratory chain complexes I, II and III suggested aberrant iron-sulfur metabolism as a common denominator; sequencing of the ISCU gene revealed the previously described g.7044G N C ISCU intronic mutation [8, 9] . To investigate the disease mechanism, particularly why the disorder is clinically restricted to skeletal muscle, we studied different tissues from our patient. ISCU has been found to be widely expressed in man, though highest in heart and skeletal muscle [11] .
Our data confirm that the g.7044G N C strengthens an active, but low-affinity splice site, and that both normal and abnormal transcripts are detectable in normal tissues. The relative degree to which this occurs, however, varies between tissues. Using a semi-quantitative assay, we find that the relative amount of abnormal (i.e. that containing exon 5A) to normal transcript is 10%:90% in control muscle, but a reverse relationship exists in patient muscle, where 90% of the transcript is abnormally spliced. Our estimate of approximately 10% remaining normally spliced ISCU RNA correlates well with that found in an earlier study [8] . In blood cells, cultured fibroblasts and myoblasts from the patient, 50% or more of the ISCU transcript appears to be normally spliced.
In addition to qualitative differences, we also found that the amount of ISCU RNA varied between mature skeletal muscle and both types of cultured cell. The relative amount of ISCU RNA was approximately 4-fold higher in control cells than control skeletal muscle. In the patient's muscle, the amount of ISCU RNA was approximately 50% and in myoblasts 20% of control; the level in fibroblasts was similar to control. Thus, one explanation for the selective involvement of muscle is the combined effect of quantitative loss and qualitatively abnormal splicing. Myoblasts appear protected by having a relatively higher baseline expression and a more normal splice pattern; based on our findings, they should have an ∼8-fold higher relative amount of normally spliced ISCU RNA than muscle.
We show that the amount of ISCU protein is severely decreased in skeletal muscle; levels are also lower in the patient's myoblasts and fibroblasts. Inclusion of the aberrant exon 5A, is predicted to yield a truncated protein lacking an α-helix domain important for function and similarly to one previous study [7] we identified a protein approximately 1.5 kDa smaller than the predominant ISCU band. This species is present only in muscle and myoblasts from the patient and not controls (Fig. 2) and based on size, could represent the abnormal ISCU protein.
In order to examine the consequences of ISCU deficiency, we studied the assembly of respiratory chain complexes containing FeS centres. There are eight iron-sulfur clusters in complex I, seven of which are inserted into the peripheral matrix arm involved in linking NADH oxidation to ubiquinone reduction [19] . Lack of these could impair complex I assembly. Using antibodies against the 30 kDa subunit of complex I that is presumed to incorporate into an early assembly intermediate, we found no stalled intermediates, suggesting either that assembly only proceeds in the presence of sufficient FeS clusters or that earlier intermediates are rapidly turned over. BN PAGE did reveal, however decreased amounts of mature complex I correlating with the decreased activity suggesting that the deficient ISCU protein function does lead to complex I deficiency. Both in-gel activity and amount were normal in fibroblasts. Previous studies have shown low levels of several subunits of complexes I, II and III in skeletal muscle, but these experiments were performed under denaturing conditions [20] .
Previous studies in a yeast model lacking the iron-sulfur cluster assembly protein frataxin homologue Yfh1, have clearly shown a loss of oxidative metabolism and marked depletion of mtDNA [21] . In addition, aconitase has been reported to play a direct role in mtDNA maintenance in yeast [22] . In view of these findings, we investigated mtDNA copy number and integrity in our patient but found no evidence of mtDNA rearrangements or mtDNA depletion. Levels of mtDNA were in fact increased 6-fold in skeletal muscle compared with controls and even higher in patient myoblasts (17-fold) although unchanged in fibroblasts and blood cells. Since these findings mirrored the degree to which tissues expressed both phenotypic and biochemical deficiencies, we hypothesise that the increases in mtDNA levels reflect a secondary, compensatory response to some form of mitochondrial "stress" induced by ISCU mutation, possibly due to the accumulation of iron or free radical damage as previously described in the context of frataxin deficiency [23] . Interestingly, myoblasts manifested a massive up-regulation of mtDNA copy number suggesting that they are indeed responding to the stress induced by the ISCU deficiency, but are able to cope with this due to their high baseline ISCU expression and less severe splicing aberration.
In conclusion, our studies confirm that the g.7044 G N C ISCU mutation strengthens an active, but low-affinity splice site causing abnormal splicing and the co-occurrence of transcripts with or without an aberrant exon (exon 5A). We show that the relative amounts of abnormal to normally spliced ISCU RNA vary between tissues being most abnormal in skeletal muscle. This, together with a relatively lower starting amount of ISCU transcript suggests that tissue specific expression of the ISCU mutation is caused by the combination of qualitative and quantitative abnormalities.
